baber/WOPTO huggingface dataset:
Patent NZ-578983-A (NZ)
Title: Assays and methods to detect biomarkers predictive of sensitivity to Apo2L/TRAIL
Inventor: WAGNER KLAUS W
IPC: C12Q1/68
Filed: 2005-08-03
Abstract: Disclosed is a method for predicting the sensitivity of a mammalian tissue sample or cell sample to Apo2L/TRAIL, the method comprising the steps of: examining the mammalian tissue sample or cell sample to detect expression of one or more biomarkers selected from the group of fucosyltransferase 3, fucosyltransferase 6, sialyl Lewis A and/or X antigen(s), wherein determining that the expression of one or more of the biomarkers is higher than that observed for a control tissue sample or cell sample is predictive that said tissue sample or cell sample is sensitive to apoptosis inducing activity of Apo2L/TRAIL. The method can be used as part of the treatment for immune related disorders and cancer. (62) Divided Out of 552497
Patent NZ-590035-A (NZ)
Title: Collapsible wedge comprising a base and arm with a removable support, and a socket for removably holding a wire cable or rope
Inventor: KUBO KENNETH
IPC: F16G11/00
Filed: 2009-06-19
Abstract: 590035 Disclosed is a collapsible wedge for holding a wire rope within a socket. The wedge comprises a base and an arm coupled to the base, the arm being smaller than the base and extending substantially less than the length of diverging sides. The base and the arm collectively define a narrowed front end, an expanded rear end, with rearwardly diverging sides extending between the front and rear ends. An external channel along the sides and rear end receives the wire rope to be secured in the socket, and a removable support which maintains the arm in a spaced position relative to the base to secure the wire rope in the socket when in use and which when removed permits pivoting of the arm toward the wedge to reduce the width of the wedge and permit release of the wire rope from within the socket. The support is proximate the front end and the arm pivots toward a front end of the base, and the base includes a brace to restrict forward movement of the arm while securing the wire rope.
Patent NZ-591024-A (NZ)
Title: Substituted pyrrolidine-2-carboxamides
Inventor: DING QINGJIE
IPC: A61K31/4025
Filed: 2009-09-08
Abstract: Disclosed herein are subsitituted pyrrolidine-2-carboxamides of formula I and II, wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful in the treatment or control of cell proliferative disorders, in particular oncological disorders. The compounds and formulations containing said compounds may be particularly useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors. Particularly preferred compounds include: (2R,3R,4R,5S)-3-(3-chloro-phenyl)-4-(4-chloro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carboxylic acid (2-morpholin-5 4-yl-ethyl)-amide; (S)-2-{ [(2R,3R,4R,5S)-3-(3-chloro-phenyl)-4-(4-chloro-phenyl)-4-cyano-5-(2,2-dimethylpropyl)-pyrrolidine-2-carbonyl]-amino} -3-methyl-butyric acid methyl ester; (2S,3S,4S,5R)-3-(3-chloro-phenyl)-4-(4-chloro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carboxylic acid ((R)-1-hydroxymethyl-3-methyl-butyl)-amide; rac-(2R,3S,4R,5S)-3-(3-chloro-2-fluoro-phenyl)-4-(4-chloro-phenyl)-4-cyano-5-cyclopentylmethyl-pyrrolidine-2-carboxylic acid ((S)-3,4-dihydroxy-butyl)-amide; rac-(2R,3S,4R,5S)-3-(3-chloro-2-fluoro-phenyl)-4-(4-chloro-phenyl)-4-cyano-5-(2,2-dimethylpropyl)-pyrrolidine-2-carboxylic acid ((S)-3,4-dihydroxy-butyl)-amide; (2R,3S,4R,5S)-3-(3-chloro-2-fluoro-phenyl)-4-(4-chloro-2 -fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carboxylic acid [4-(1H-tetrazol-5-yl)-phenyl]-amide.
Patent NZ-591741-A (NZ)
Title: Benzimidazole anthelmintic compositions
Inventor: ALBRIGHT ROBERT BRUCE
IPC: A61K9/08
Filed: 2009-10-02
Abstract: Disclosed is a veterinary anthelmintic composition comprising: a) at least 10 percent w/v of a benzimidazole anthlemintic selected from the group consisting of thiabendazole, cambendazole, parbendazole, mebendazole, fenbendazole, oxfendazole, oxibendazole, albendazole, triclabendazole, salts thereof and combinations thereof; and b) a water-immiscible solvent system, which comprises a lactone solvent, an essential oil, and surfactant, wherein the lactone solvent is selected from the group consisting of gamma-hexalactone, delta-hexalactone, delata-nonalactone, delta-nonalactone, delta-decalactone, delta-decalactone, gamma-dodecalactone, gamma-dodecalactone and combinations thereof for the treatment of a parasite in a homeothermic animal.
Patent NZ-592707-A (NZ)
Title: Electrical machine and method for the manufacturing of stator sections therefor
Inventor: IDLAND FREDRIK
IPC: H02K21/24
Filed: 2009-11-04
Abstract: Disclosed is an electrical machine with a rotor (13) with magnets (17) carried by an annular carrier (14, 15). The magnets create a magnetic field over an air gap between two rotor parts, within which an ironless stator (12) with windings is arranged. The stator is assembled of sections (12) with channels for circulation of coolant. The stator has windings with an annular, compact central part providing an active region of the stator. A method for manufacturing stator sections for such electrical machines is also described.
Patent NZ-593058-A (NZ)
Title: (r)-3-(e)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy) pyridine, its salts, its synthesis and its use as ligand for nicotinic acetylcholinergic receptors
Inventor: AKIREDDY SRINIVISA RAO
IPC: A61K31/4439
Filed: 2009-11-30
Abstract: 593058 Disclosed is (R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine mono-L-malate or a hydrate or solvate thereof. Also disclosed is a pharmaceutical composition comprising the compound and the use of the compound in the manufacture of a medicament for the treatment of NNR mediated disorders such as CNS disorders, inflammation, inflammatory response associated with bacterial and/or viral infection, pain, metabolic syndrome, autoimmune disorders wherein the CNS disorder is selected from cognitive dysfunction in schizophrenia (CDS), Alzheimers Disease (AD), attention deficit disorder (ADD), pre-senile dementia (early onset of Alzheimer's Disease), dementia of the Alzheimer's type, mild cognitive impairment, age associated memory impairment, and attention deficit hyperactivity disorder (ADHD).
Patent NZ-597315-A (NZ)
Title: Environmentally-friendly cementitious articles, formulations, methods of making and uses
Inventor: SULLIVAN RYAN MATTHEW
IPC: C02F1/42
Filed: 2010-06-14
Abstract: Patent No. 597315 Disclosed is a method of recycling spent process water from a cementitious shaped article forming process comprising: removing calcium, sodium, and potassium ions from the spent process water to provide a process water with a reduced metal ion content, wherein calcium ions are first removed before sodium and potassium ions are removed from the spent process water; converting calcium to a calcium salt: adding calcium from the calcium salt to the process water to produce a calcium enriched process water with a reduced potassium and sodium ion content; and reintroducing at least a portion of the calcium enriched process water with a reduced metal ion content into the cementitious shaped article forming process. Also disclosed is a cementitious shaped article manufacturing system, comprising: a forming unit adapted to form a cementitious shaped article, wherein the forming unit discharges spent process water containing calcium, sodium, and potassium ions; and a closed-loop water treatment system, said water treatment system comprises a plurality of ion exchangers, wherein at least one of the ion exchangers is adapted to remove at least one ofthe ions present in the spent process water. Also disclosed is a system for manufacturing a cementitious building article comprising: a cementitious forming process; an alkali removal process incorporating a partially closed-loop water recycling system, said alkali removal process comprises at least two sets of ion exchangers operating in parallel; and wherein the cementitious forming process is in cooperation with the alkali removal process such that at least a portion of the water exiting the cementitious forming process is recycled through the alkali removal process which results in process water having a reduced alkali content.
Patent NZ-600339-A (NZ)
Title: Drug selection for breast cancer therapy using antibody-based arrays
Inventor: SINGH SHARAT
IPC: C07K1/22
Filed: 2009-02-24
Abstract: 600339 A method for detecting the presence of a truncated receptor, said method comprising: (a) Incubating a cellular extract with beads (chromatography or dynabeads) specific for an extracellular domain (ECD) binding region of a full-length receptor; (b) removing said plurality of beads, thereby removing said full-length receptor to form a cellular extract devoid of said full-length receptor; (c) Performing and ELISA test on the cellular extract using antibodies which are specific for an intracellular domain (ICD) of the truncated receptor Wherein the truncated receptor is p95ErbB2 and the full-length receptor is ErbB2 (HER-2).
Patent NZ-601970-A (NZ)
Title: A synergistic fungicidal composition comprising pyrimethanil and fluazinam
Inventor: MOLLOY CHRISTOPHER
IPC: A01N27/00
Filed: 2012-08-22
Abstract: The disclosure relates to fungicidal composition suitable for use as an agricultural/horticultural fungicide comprising pyrimethanil (4,6-dimethyl-n-phenyl-2-pyrimidinamin) and fluazinam (3-chloro-N-[3-chloro-2,6-dinitro-4-(trifluromethyl)phenyl]-5-(trifluromethyl)-2-pyridinamine), as active ingredients. Preferably in a ratio of 20:1 to1:5 by weight to selectively control or suppress fungal growth.
Patent NZ-603917-A (NZ)
Title: A sign with image fixed between UV resistant, transparent outer layer and backing layer by a double sided adhesive layer.
Inventor: WILLS GEOFFREY CHARLES
IPC: B32B7/12
Filed: 2012-11-29
Abstract: 603917 A sign is disclosed having an ultraviolet resistant transparent outer layer (1) and a substantially rigid or semi-rigid backing layer (5). A double sided adhesive sheet (4) is disposed between the transparent (1) and backing (5) layers with imagery (2) between the UV resistant transparent layer (1) and adhesive (4) layer viewable through the transparent layer (1).
Patent NZ-607555-A (NZ)
Title: Dexmedetomidine premix formulation
Inventor: PRIYANKA ROYCHOWDHURY
IPC: A61P25/04
Filed: 2012-06-18
Abstract: Provided are liquid ready to use formulations of dexmedetomidine. Preferably the formulations comprise between 0.05 micrograms/mL and 15 micrograms/mL of dexmedetomidine, are stored in sealed glass containers and can be administered without dilution. Dexmedetomidine has analgesic and sedative activity.
Patent NZ-627211-A (NZ)
Title: Humanized light chain mice
Inventor: MACDONALD LYNN
IPC: C12N9/64
Filed: 2012-12-17
Abstract: Disclosed is a non-human animal whose genome comprises: (a) an insertion of one or more human Vλ gene segments and one or more human Jλ gene segments upstream of a non-human immunoglobulin light chain constant region gene, (b) an insertion of one or more human VH gene segments, one or more human DH gene segments and one or more human JH gene segments upstream of a non-human immunoglobulin heavy chain constant region gene, and (c) an ectopic nucleic acid sequence that encodes an ADAM6 protein or a functional fragment thereof, wherein the ADAM6 protein or functional fragment thereof is expressed from the ectopic nucleic acid sequence.
Patent NZ-628144-A (NZ)
Title: Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
Inventor: SOLL MARK D
IPC: C07D261/04
Filed: 2013-01-31
Abstract: Disclosed is a soft chewable veterinary composition for treating and/or preventing a parasitic infection or infestation (such as fleas (e.g. Ctenocephalides spp., Ctenocephalides felis etc.), ticks (e.g. Rhipicephalus spp., Ixodes spp., Dermacentor spp., Amblyoma spp., Haemaphysalis spp., etc.), mites (e.g. Demodex spp., Sarcoptes spp., Otodectes spp., Cheyletiella spp., etc.), lice (e.g. Trichodectes spp., Felicola spp., Linognathus spp., etc.)) in an animal comprising: a) at least one isoxazoline / afoxolaner / fluralaner analogue or derivative of Formula (I) (wherein the substituents are as defined herein); and b) a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises one or more surfactants selected from polyethylene glycol stearate and a polyethylene glycol hydroxystearate. Also disclosed is a soft chewable veterinary composition comprising ingredients such as afoxolaner, Soy Protein Fines, a flavour additive (e.g. beef flavour), Povidone K-30, PEG 400, polyethylene glycol 12-hydroxystearate and Caprylic/capric triglyceride.
Patent NZ-702914-A (NZ)
Title: Ite for cancer intervention and eradication
Inventor: SONG JIASHENG
IPC: C07D277/56
Filed: 2010-10-14
Abstract: Claimed is the use of ITE (2-(1’H-indole-3’-carbonyl)-thiazole-4-carboxylic acid methyl ester / 2-(1H-indol-3-ylcarbonyl)-4-thiazolecarboxylic acid methyl ester / methyl 2-(1H-indol-3-ylcarbonyl)-1,3-thiazole-4-carboxylate) or one of its analogues as represented by the general formula (I) in the manufacture of a medicament for treating a cancer selected from the group consisting of: prostate, liver, lung, ovarian and breast cancer, in a patient in need thereof, wherein the medicament is formulated to deliver to the patient between 1 and 80 mg/kg of the compound; wherein X and Y are independently selected from O or S; R1, R2, R3, R4, RN, R5 and R7, are independently selected from hydrogen or halogen; and R6 is -C(=O)-R10; wherein R10 is selected independently from methoxy, ethyl or methylamino. In particular the most preferred compounds now disclosed include 2-(1H-indol-3-ylcarbonyl)-N-methyl-1,3-thiazole-4-carboxamide / N-methyl-2-(1H-indol-3-ylcarbonyl)-1,3-thiazole-4-carboxamide (abbreviated as ITA) and 1-[2-(1H-indol-3-ylcarbonyl)-1,3-thiazol-4-yl]propan-1-one (ITK). It is suggested that such compounds including 2-(1H-indol-3-ylcarbonyl)-N-methyl-1,3-thiazole-4-carboxamide are provided for the treatment of prostate cancer, liver cancer, lung cancer, ovarian cancer or breast cancer, at a dosing schedule of once or twice daily in an amount between 1 and 10 mg/kg.
Patent NZ-703366-A (NZ)
Title: Factor viii complex with xten and von willebrand factor protein, and uses thereof
Inventor: CHHABRA EKTA SETH
IPC: C12P21/08
Filed: 2013-07-10
Abstract: The present invention includes a chimeric protein comprising a VWF protein with D’ domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain of a VWF fragment is associated with a FVIII polypeptide chain linked to an XTEN sequence. The VWF fragment polypeptide chain can prevent or inhibit binding of endogenous VWF to FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to FVIII protein, VWF fragment can extend half-life of chimeric protein comprising FVIII protein. The invention includes nucleotides, vectors, host cells, use of VWF fragment, or chimeric proteins.
Patent NZ-707173-A (NZ)
Title: Radiant barrier for heated air circuits
Inventor: LABOLLITA STEVE
IPC: A61M16/10
Filed: 2011-12-12
Abstract: A breathing circuit (100) comprising: an airflow conduit (110) configured to receive gas at input end and configured to deliver the gas to a patient at an output end; a heating element (129) disposed inside the airflow conduit configured to heat the gas, at least partially by emitting infrared radiation to be absorbed by water vapor inside the airflow conduit to maintain a predetermined temperature inside the airflow conduit to prevent condensation of the gas between the input end and the output end; and a heat shield (200) disposed on an interior surface (118) of the airflow conduit such that the heat shield prevents energy loss from within the airflow conduit. The heat shield comprises an infrared shield configured to prevent absorption of the infrared radiation by the airflow conduit.
Patent NZ-714684-A (NZ)
Title: Stable oral solutions for combined api
Inventor: COHEN DANIEL
IPC: A61K47/26
Filed: 2014-06-05
Abstract: The present invention relates to a homogenous, stable, and palatable pharmaceutical solution comprising, baclofen, sorbitol and naltrexone where the stability is achieved by an acetate or citrate buffer, suitable for the treatment of nervous system diseases such as Charcot-Marie-Tooth disease.
Patent NZ-715915-A (NZ)
Title: An assembly for generating electricity
Inventor: KOURIS PAUL
IPC: F03B13/10
Filed: 2014-08-04
Abstract: An assembly for generating electricity from flowing water includes a chamber having a base, a side wall extending from the base, a water inlet, and a water outlet, a rotor unit having a shaft and a rotor mounted to the shaft located in and rotatable in the chamber in response to water flow through the chamber, and an electrical generator coupled to the rotor unit for generating electricity in response to rotation of the rotor. The dimensions of the inlet, the outlet and the chamber and the positions of the inlet, the outlet and the rotor are selected to promote the formation of a vortex within the chamber when in use the assembly is located in a body of water or beside a body of water, in a waterway or beside a waterway, within an enclosed water conduit or beside an enclosed water conduit, and there is a flow of water through the chamber from the inlet to the outlet.
Patent NZ-731596-A (NZ)
Title: Methods for treating conditions associated with masp-2 dependent complement activation
Inventor: DEMOPULOS GREGORY A
IPC: A61P7/00
Filed: 2012-04-06
Abstract: Disclosed is the use of a MASP-2 inhibitory agent, which is an antibody (or fragment thereof) which binds a portion of human MASP-2, which inhibits MASP-2-dependent complement activation in the manufacture of a medicament for decreasing the likelihood that a subject at risk for developing hemolytic uremic syndrome (HUS), or is suffering from HUS, will develop impaired renal function. Said subject presents which bloody diarrhea and tests positive for infection with enterogenic E. coli. Also disclosed is the use of said inhibitory agent in the treatment of HUS wherein the medicament is formulated for administration to the subject via an intravenous catheter or other catheter delivery method. Also disclosed is the treatment of cryoglobulinemia, cold agglutinin disease, glaucoma and acute radiation syndrome.
Patent NZ-732983-A (NZ)
Title: Infusion system with concurrent tpn/insulin infusion
Inventor: SILEIKA TADAS S
IPC: A61M5/148
Filed: 2015-12-18
Abstract: In present practice, TPN solution administration is reduced from the required dosing for the patient to minimize hyperglycemia and avoid glucose shock. Insulin is premixed in the same IV bag or container with the TPN solution based on calculated requirements for the patient, adding to clinician time and risk of error. Insulin dosing also requires modulation based on monitored glucose levels during infusion. Subcutaneous insulin infusions can be administered to compensate for advancing hyperglycemia, but for hypoglycemic situations increased TPN (and specifically dextrose) delivery is indicated. Thus, infusion of both TPN and insulin as presently practiced is complex and time consuming. Accordingly, an infusion system to provide concurrent TPN/insulin infusion is provided to address the above disadvantages, including: a fluid administration set having a primary line in fluid communication with the TPN source, a secondary line in fluid communication with the insulin source, and a common outlet line; a pump operable to removably receive the fluid administration set, the pump being operable to concurrently move the TPN solution through the primary line in response to a TPN solution flow rate signal and the insulin solution through the secondary line in response to an insulin solution flow rate signal; and a flow controller operable to provide the TPN solution flow rate signal and the insulin solution flow rate signal to the pump. The flow controller is further operable to vary the TPN solution flow rate signal and the insulin solution flow rate signal to vary a ratio of TPN solution to insulin solution provided to the common outlet line.
Patent NZ-738011-A (NZ)
Title: A method and an apparatus for washing a crude lignin, a soluble carbohydrate containing fraction, a solid fraction and their use
Inventor: TURUNEN SAMI
IPC: C07G1/00
Filed: 2016-05-26
Abstract: The invention relates to a method and an apparatus for washing a crude lignin slurry (5) formed from plant based raw material, wherein the method comprises separating a soluble carbohydrate containing fraction (10) from the crude lignin slurry (5) by using displacement washing in at least one solid-liquid separation stage (6) so that the crude lignin slurry is prepressed, washed and pressed, and recovering a solid fraction (11) and the soluble carbohydrate containing fraction (10). Further, the invention relates to the soluble carbohydrate containing fraction and the solid fraction, and their uses.
Patent NZ-743274-A (NZ)
Title: Substituted tricyclic compounds as fgfr inhibitors
Inventor: WU LIANGXING
IPC: C07D498/14
Filed: 2013-06-12
Abstract: The present invention relates to tricyclic compounds of Formula II, and the preparation of pharmaceutical compositions of the same, that are useful in the treatment of fibrotic disease.
Patent NZ-751639-A (NZ)
Title: Methods of using zscan4 for rejuvenating human cells
Inventor: KO MINORU
IPC: A61K48/00
Filed: 2014-03-14
Abstract: The present disclosure relates to uses of Zscan4 for manufacture of a medicament for treating a subject with a disease or disorder associated with a karyotype abnormality.
Patent NZ-753426-A (NZ)
Title: Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
Inventor: CHARPENTIER EMMANUELLE
IPC: C12N15/63
Filed: 2013-03-15
Abstract: The present disclosure provides a genetically modified eukaryotic cell comprising a DNA-targeting RNA and/or one or more nucleic acids that encode the DNA targeting RNA, wherein the DNA-targeting RNA comprises: (i) a DNA-targeting segment comprising a nucleotide sequence that is complementary to a sequence in the target DNA, and (ii) a protein-binding segment that interacts with a Cas9 polypeptide, wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex, wherein said two complementary stretches of nucleotides are not linked to one another by intervening nucleotides, wherein said dsRNA duplex comprises complementary nucleotides of a tracrRNA and a CRISPR RNA (crRNA). The cell may further comprise a a Cas9 polypeptide and/or a nucleic acid comprising a nucleotide sequence that encodes the Cas9 polypeptide.